Arna Katewa

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development

James J. Crawford, Adam R. Johnson, Dinah Misner et al. · Journal of Medicinal Chemistry · 2018 · 247 citations · Full text

Medicine, Immunology, Pharmacology +17

CD8 T Cells Utilize TRAIL to Control Influenza Virus Infection

Erik L. Brincks, Arna Katewa, Tamara A. Kucaba et al. · The Journal of Immunology · 2008 · 194 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

A Synthetically Simple, Click-Generated Cyclam-Based Zinc(II) Sensor

Emiliano Tamanini, Arna Katewa, Lisa M. Sedger et al. · Inorganic Chemistry · 2008 · 159 citations

Engineering, Cell Biology, Medicinal Chemistry +15

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations

Adam R. Johnson, Pawan Bir Kohli, Arna Katewa et al. · ACS Chemical Biology · 2016 · 134 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Overcoming Preclinical Safety Obstacles to Discover (<i>S</i>)-<i>N</i>-((1,2,3,5,6,7-Hexahydro-<i>s</i>-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5<i>H</i>-pyrazolo[5,1-<i>b</i>][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor

Christopher McBride, Lynnie Trzoss, Davide Povero et al. · Journal of Medicinal Chemistry · 2022 · 73 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17